New Delhi, Apr 18 (PTI) Zydus Lifesciences on Tuesday said it has received approval from the US regulator to market a generic female hormone, which helps reduce symptoms of menopause, in the US market.

The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Estradiol Transdermal System USP in the American market.

Also Read | Heatwave Warning: IMD Issues Season's First Heat Wave Alert for 11 Districts in Jharkhand for Two Days, Temperatures May Rise Above 44 Degrees Celsius.

Estradiol transdermal system is indicated for prevention of postmenopausal osteoporosis.

The company said the drug will be manufactured at the group's formulation manufacturing facility in Moraiya, Ahmedabad in Gujarat.

Also Read | Layoffs, Hiring Slowdown: Nearly Half of Employees Don't Plan To Switch Jobs in 2023, Says Report.

As per the IQVIA sales data, Estradiol Transdermal System had annual sales of USD 1.9 million in the US.

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)